https://scholars.lib.ntu.edu.tw/handle/123456789/604462
Title: | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE | Authors: | Mamounas E. P. Untch M. Mano M. S. CHIUN-SHENG HUANG Geyer C. E. von Minckwitz G. Wolmark N. Pivot X. Kuemmel S. DiGiovanna M.P. Kaufman B. Kunz G. Conlin A.K. Alcedo J.C. Kuehn T. Wapnir I. Fontana A. Hackmann J. Polikoff J. Saghatchian M. Brufsky A. Yang Y. Zimovjanova M. Boulet T. Liu H. Tesarowski D. Lam L.H. Song C. Smitt M. Loibl S. |
Keywords: | HER2; adjuvant; peripheral neuropathy; residual invasive early breast cancer; thrombocytopenia | Issue Date: | 2021 | Publisher: | ELSEVIER | Journal Volume: | 32 | Journal Issue: | 8 | Start page/Pages: | 1005 | Source: | Annals of oncology : official journal of the European Society for Medical Oncology | Abstract: | In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604462 | ISSN: | 0923-7534 | DOI: | 10.1016/j.annonc.2021.04.011 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.